Preeclampsia is a life-threatening hypertensive disorder involving the heart and
vasculature affecting 5-8% of pregnancies. Untreated, 2-10% of women develop eclampsia,
defined as new onset of seizures in the setting of preeclampsia. Eclamptic seizures are
estimated to occur in 2-8 per 10.000 deliveries in high-income countries (HIC) and with a
higher prevalence of up to 16-69 per 10.000 deliveries in low-income countries (LIC).
Eclampsia is associated with significant maternal and neonatal morbidity, with a case
fatality rate as high as 25-50 % in LIC, and associated with a 16-26 fold odds of death
in HIC. Associated maternal complications include intracranial hemorrhage (ICH), cerebral
edema, acute kidney injury, acute respiratory syndrome (ARDS), cardiac failure,
coagulopathy and postpartum hemorrhage. Obstetric and medical management include seizure
prophylaxis and control, aggressive blood pressure management and the urgent delivery of
the baby. Anesthesia management can be challenging and has to be tailored to the clinical
condition of the eclamptic woman. Unless the usual contraindications to regional
anesthesia (RA) apply, spinal anesthesia (SPA) has been described as the method of choice
in parturients in whom the Glasgow Coma Scale (GCS) is ≥ 14, and cardiac failure is
absent. For patients with persistent decreased level of consciousness, general anesthesia
(GA) is recommended. However, in eclamptic women both anesthesia techniques may be
associated with significant complications. Raised intracranial pressure (ICP) present in
eclamptic women raises the possibility of cerebellar tonsillar herniation in association
with SPA. Cardiac diastolic dysfunction, with or without preserved ejection fraction, has
been described in preeclamptic women. With preserved ejection fraction, induction of RA
or GA is generally hemodynamically well tolerated. However, in women with decreased
systolic function, induction of anesthesia can lead to life-threatening cardiovascular
collapse, which may only be prevented by cautious titration of anesthesia agents. This
might be in conflict with the need to administer high dosages of induction agents to
blunt the hypertensive response to tracheal intubation that, if untreated, may lead to
life-threatening ICH and pulmonary edema. Consequently, early detection of increased ICP
and knowledge of cardiopulmonary function in the individual case are essential to the
obstetric anesthetist to guide appropriate management.
Cardiopulmonary and optic nerve sheath point-of-care ultrasound (POCUS) protocols might
be particularly suitable for this purpose. These involve a defined bedside ultrasound
examination to identify critical cardiopulmonary pathophysiology, which may remain
undetected by clinical examination alone. The identification of increased optic nerve
sheath diameter (ONSD) on ultrasound may suggest raised ICP.
It is further well documented that the serum brain natriuretic peptide (BNP) level, a
marker of cardiac dysfunction, is increased in preeclampsia. However, no data is
available to confirm that elevated BNP levels identify those eclamptic women at risk for
cardiopulmonary abnormalities.
Therefore, this study is planned to describe the prevalence and severity of cardiac, lung
and ONS US abnormalities in women with eclampsia.